Summary of the R&D update held earlier today

Medivir held a short presentation this morning for analysts, journalists and institutional investors. The presentation from this research & development update is available on our website under the heading IR & Media/Latest Events. During October 2009, Medivir commenced a thorough portfolio evaluation with the aim of creating a focused product portfolio for development in conjunction with partners or in-house. A further goal has been to identify future project opportunities within Medivir’s major area of competence; anti-infectives. Greater focus on infectious diseases As the current in-house projects reach their optimal development stage for engaging in partnerships, resources will be released to enable new infectious disease projects to be commenced. The project portfolio now consists of nine projects plus Xerclear™. Six of these projects relate to anti-infectives and six are partnered, of which with Tibotec/Johnson & Johnson account for three. The remaining projects are owned and will be run in-house by Medivir until appropriate decision points for partnership are reached. Xerclear™ launched in Sweden 15 March Medivir’s cold sore pharmaceutical, Xerclear™, will be launched next week in Sweden as an Rx pharmaceutical (prescription-only), shortly followed by Finland. Preparations for an OTC (prescription-free) launch in Denmark and Sweden are underway and will be carried out either in conjunction with a European partner or within the Medivir organisation. Negotiations are underway with potential partners for the European markets, with the goal of designating a partner during Q2. Meda AB is Medivir’s partner for the product in the USA.